



RECEIVED
SEP 16 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Dikstein et al.

Art Unit : 1642

Serial No. : 09/763,909

Examiner : Minh-Tam B. Davis

Filed : June 8, 2001

Title : A TRANSCRIPTION FACTOR TFIID SUBUNIT, TAFII105, POLYPEPTIDES,
DNA ENCODING THEREFOR AND PHARMACEUTICAL COMPOSITIONS

U.S. Patent and Trademark Office
Arlington, VA 22202

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the action mailed August 6, 2002, Applicants respectfully traverse the restriction of Group I and Group XVI, as set forth below:

Group I: Claims 1-2, 6, 12-13, 15-19, drawn to a DNA molecule encoding a fragment of the wild type TAF11 105 polypeptide of SEQ ID NO:2 or a fragment of the wild type polynucleotide of SEQ ID NO:1, an expression vector comprising said DNA molecule, an antisense of SEQ ID NO:1, a method for promotion of apoptosis, comprising administering a DNA sequence encoding a fragment of the wild type TAF11 105 polypeptide;

Group XVI: Claim 17, drawn to a method for promotion of apoptosis, comprising administering an antisense sequence of SEQ ID NO:1.

I. TRAVERSAL AND REQUESTED JOINDER OF GROUPS I AND XVI.

Applicants respectfully request joinder of Groups I and XVI in the present invention as a search of the combined groups would not create an undue burden upon the Examiner. Applicants respectfully submit that a search of the subject matter of Group I would encompass searching antisense molecules of SEQ ID NO:1 as well as methods for promotion of apoptosis. A search of Group XVI would encompass a search of antisense molecules for SEQ ID NO:1 and methods of promoting apoptosis. Accordingly, Applicants respectfully submit that joinder of

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202.

Date of Deposit

September 6, 2002

Signature

Lucille M. Begalla

Typed or Printed Name of Person Signing Certificate

Lucille M. Begalla

10
KO
9-15-02

Applicant : Dikstein et al.
Serial No. : 09/763,909
Filed : June 8, 2001
Page : 2

Attorney's Docket No.: 13005-002001 / 131519.4 / 131519.4

RECEIVED
SEP 16 2002
TECH CENTER 1600/2900

Group I and XVI in the present application would not create an undue search burden on the Examiner.

II. GROUP ELECTION


In order to be fully compliant with the Restriction Requirement, Applicants elect the invention of Group I, claims 1-2, 6, 12-13, 15-19, drawn to a DNA molecule encoding a fragment of the wild type TAF₁₁ 105 polypeptide of SEQ ID NO:2 or a fragment of the wild type polynucleotide of SEQ ID NO:1, an expression vector comprising said DNA molecule, an antisense of SEQ ID NO:1, a method for promotion of apoptosis, comprising administering a DNA sequence encoding a fragment of the wild type TAF₁₁ 105 polypeptide. This election is made with traverse.

III. SPECIES ELECTION

In addition, Applicants elect the species of "inflammation". This species is readable on claim 19.

This response is being filed within one (1) month of the mailing date of the Restriction Requirement and thus the response is being timely filed. Accordingly, no fee is believed to be due. However, should any required fee be due, please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,



Joseph R. Baker, Jr.
Reg. No. 40,900

Date: 9/6/02

Fish & Richardson P.C.
4350 La Jolla Village Drive, Suite 500
San Diego, California 92122
Telephone: (858) 678-5070
Facsimile: (858) 678-5099